Drugs / INO-5401
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04367675 | Apr 2021 → Dec 2026 expected | hereditary neoplastic syndrome | Abramson Cancer Center at Penn Medicine | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03502785 | Jul 2018 → May 2025 | urothelial carcinoma | Inovio Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT03491683 | May 2018 → Dec 2026 expected | glioblastoma | Inovio Pharmaceuticals | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2022-05-27 | Inovio Pharmaceuticals | Results INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022 inovio.com ↗
Overall, INO-5401 + INO-9012 is demonstrated to be tolerable and immunogenic when administered with Libtayo and RT/TMZ (radiation and temozolomide) to newly diagnosed GBM patients. |
| 2020-11-20 | Inovio Pharmaceuticals | Results INOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting inovio.com ↗
The study demonstrated that INO-5401 + INO-9012 with Libtayo, radiation (RT) and temozolomide (TMZ) are tolerable, immunogenic, and may improve median survival for patients with newly diagnosed GBM. |
| 2020-05-26 | Inovio Pharmaceuticals | Results INOVIO to Host Webinar "DNA Medicines: From COVID-19 to Cancer" inovio.com ↗ |
| 2020-05-14 | Inovio Pharmaceuticals | Results INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment inovio.com ↗
The Phase 1/2 clinical trial demonstrated that 84.4% percent (27 of 32) of patients with MGMT promoter unmethylated tumors, and 85% (17 of 20) of patients with MGMT promoter methylated tumors were alive at 12 months. |
| 2019-11-05 | Inovio Pharmaceuticals | Results Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab) inovio.com ↗
80% of Methylated Patients and 75% of Unmethylated Patients Were Disease Progression-Free at 6 Months |
All press releases naming this drug 7 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-5401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03502785 ↗ |
| Modality | Other / unclassified | “INO-5401 is a combination of 3 separate DNA plasmids” NCT03491683 ↗ |
| Route | Intramuscular | “will be delivered IM followed by EP” NCT03491683 ↗ |
| Target | WT1 | “targeting Wilms tumor gene-1 (WT1) antigen” NCT03491683 ↗ |